💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Deutetrabenazine

CHEMBL3137326 Phase 4 Approved Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
323.5 g/mol
LogP
2.9
Phase
4

A deuterium-substituted form of tetrabenazine that inhibits vesicular monoamine transporter 2 (VMAT2), reducing the amount of dopamine and other monoamines released at nerve terminals; used for chorea associated with Huntington's disease and tardive dyskinesia. The deuterium substitution slows metabolism, allowing twice-daily dosing.

Molecular Weight

323.5000 g/mol

LogP

2.90

TPSA

38.80 Ų

Lipinski RO5

Pass

Therapeutic Areas

Bipolar Disorder Major Depressive Disorder Schizophrenia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
[2H]C([2H])([2H])Oc1cc2c(cc1OC([2H])([2H])[2H])C1CC(=O)C(CC(C)C)CN1CC2

                

                

                
                

                    
InChI

                    
InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/i3D3,4D3

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H27NO3

                    

                    
                    

                        
HBD / HBA

                        
- / 4

                    

                    
                    

                        
Rotatable Bonds

                        
4

                    

                    
                    
                    

                        
Heavy Atoms

                        
23

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Frequently Asked Questions

                

                    
                    

                        
                        

                            
A deuterium-substituted form of tetrabenazine that inhibits vesicular monoamine transporter 2 (VMAT2), reducing the amount of dopamine and other monoamines released at nerve terminals; used for chorea associated with Huntington's disease and tardive dyskinesia. The deuterium substitution slows metabolism, allowing twice-daily dosing.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Deutetrabenazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3137326.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 73442840.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medical Disclaimer

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.